[CAS NO. 2055602-83-8] BAY-1797
PRODUCTS SPECIFICATIONS [2055602-83-8]
DESCRIPTION [2055602-83-8]
Overview
| MDL | MFCD32689580 |
|---|---|
| Molecular Weight | 416.88 |
| Molecular Formula | C20H17ClN2O4S |
| SMILES | O=C(NC1=CC=C(OC2=CC=CC(Cl)=C2)C(S(=O)(N)=O)=C1)CC3=CC=CC=C3 |
2 Publications Citing Use of MCE
Summary
BAY-1797 is a potent, orally active, and selective P2X4 antagonist, with an IC 50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects [1] .
IC50 & Target
IC50: 211 nM (human P2X4), >50 μM (human P2X1), >30 μM (human P2X23), 8.3 μM (human P2X3), 10.6 μM (human P2X7) [1]
In Vitro
BAY-1797 inhibits human, mouse, and rat P2X4 in 1321N1 cells with IC
50
s of 108 nM, 112 nM, and 233 nM, respectively
[1]
.
BAY-1797 exerts no measurable activity on hERG and carbonic anhydrase II (both IC
50
>10 μM). BAY-1797 is also tested against a panel of off-targets, including G-protein coupled receptors (GPCRs), ion channels, kinases, and transporters at 10 μM. An inhibitory activity against the dopamine transporter (DAT, IC
50
2.17 μM) was revealed as the only hit
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BAY-1797 (12.5-50 mg/kg; p.o.) shows a significant induction of PGE2 levels in the inflamed paw in the mouse Complete Freund’s Adjuvant (CFA) inflammatory pain model
[1]
.
BAY-1797 (50 mg/kg; once daily for multiple p.o. administrations) induces a significant reduction of the ipsilateral paw load 24 and 48 h after CFA injection
[1]
.
BAY-1797 treatment shows the AUC
norm
, V
ss
and t
1/2
are 1.06 kg h/L, 3.67 L/kg and 2.64 hours, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female adult C57BL/6N mice (CFA inflammatory pain model) [1] |
| Dosage: | 12.5, 25, 50 mg/kg |
| Administration: | p.o.; once |
| Result: | Dose-dependently reduced PGE2 concentration in inflamed paw. |
| Animal Model: | Rat male Wistar [1] |
| Dosage: | 1 mg/kg |
| Administration: | i.v. (Pharmacokinetic Analysis) |
| Result: | The AUC norm , V ss and t 1/2 were 1.06 kg h/L, 3.67 L/kg and 2.64 hours, respectively. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 599.69 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3988 mL | 11.9939 mL | 23.9877 mL |
| 5 mM | 0.4798 mL | 2.3988 mL | 4.7975 mL |
| 10 mM | 0.2399 mL | 1.1994 mL | 2.3988 mL |
